Roivant to Participate in September Investor Events

Rhea-AI Summary

Roivant Sciences (Nasdaq: ROIV) will participate in three healthcare investor conferences this September in Boston, New York, and London. The schedule includes:

• Citi BioPharma Conference in Boston on September 7
• H.C. Wainwright Global Investment Conference in New York on September 12, with CEO Matt Gline presenting at 8:30 a.m. EDT
• Bank of America Global Healthcare Conference in London on September 16

Additionally, Roivant will host a virtual Investor Day on September 28 at 11:00 a.m. EDT.

• Three healthcare investor conferences in September across Boston, New York and London
• Roivant Investor Day will take place virtually on September 28^th starting at 11 a.m. EDT

BASEL, Switzerland and LONDON and NEW YORK and BOSTON, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Roivant Sciences (Nasdaq: ROIV) will participate in three healthcare investor conferences and hold an investor day in September:

• Citi BioPharma Conference in Boston on Wednesday, September 7^th
• H.C. Wainwright Global Investment Conference in New York City on Monday, September 12^th. Roivant’s CEO Matt Gline will present at 8:30 a.m. EDT (webcast available at https://investor.roivant.com/news-events/events)
• Bank of America Global Healthcare Conference in London on Friday, September 16^th
• Roivant virtual Investor Day on Wednesday, September 28^th at 11:00 a.m. EDT (register at https://hopin.com/events/roivantinvestorday2022/registration)

About Roivant Sciences
Roivant's mission is to improve the delivery of healthcare to patients by treating every inefficiency as an opportunity. Roivant develops transformative medicines faster by building technologies and developing talent in creative ways, leveraging the Roivant platform to launch 'Vants' – nimble and focused biopharmaceutical and health technology companies. For more information, please visit www.roivant.com.

Roivant Sciences Forward-Looking Statements

This press release contains forward-looking statements. Statements in this press release may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), which are usually identified by the use of words such as "anticipate," "believe," "continue," "could," "estimate," "expect," "intends," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "would" and variations of such words or similar expressions. The words may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act.

Our forward-looking statements include, but are not limited to, statements regarding our or our management team's expectations, hopes, beliefs, intentions or strategies regarding the future, and statements that are not historical facts, including statements about the clinical and therapeutic potential of our product candidates, the availability and success of topline results from our ongoing clinical trials and any commercial potential of our product candidates. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements.

Although we believe that our plans, intentions, expectations and strategies as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a number of risks, uncertainties and assumptions, including, but not limited to, those risks set forth in the Risk Factors section of our filings with the U.S. Securities and Exchange Commission. Moreover, we operate in a very competitive and rapidly changing environment in which new risks emerge from time to time. These forward-looking statements are based upon the current expectations and beliefs of our management as of the date of this press release, and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as required by applicable law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts

Investors
Roivant Investor Relations
ir@roivant.com

Media
Paul Davis
Roivant Sciences
paul.davis@roivant.com

FAQ

What events is Roivant Sciences participating in September 2022?

Roivant Sciences is participating in three investor conferences: the Citi BioPharma Conference on September 7, the H.C. Wainwright Global Investment Conference on September 12, and the Bank of America Global Healthcare Conference on September 16.

When is Roivant's virtual Investor Day scheduled?

Roivant's virtual Investor Day is scheduled for September 28, 2022, at 11:00 a.m. EDT.

Who will present at the H.C. Wainwright Conference?

Roivant's CEO, Matt Gline, will present at the H.C. Wainwright Global Investment Conference on September 12, 2022, at 8:30 a.m. EDT.

Where can I find more information about Roivant Sciences' events?

More information about Roivant Sciences' investor events can be found on their official investor relations page.

What is the stock symbol for Roivant Sciences?

The stock symbol for Roivant Sciences is ROIV, and the warrants are represented by ROIVW.